Noncardiotoxic pharmaceutical compounds
The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.
1. A pharmaceutical composition comprising a compound having the formula
where R 1 and R 2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, or cycloalkyl having from 3 to about 6 carbon atoms, A is a lower alkyl, lower heteroalkyl or cycloalkyl, R 20 is hydrogen, phenyl or lower alkyl, W is carbon or nitrogen, R 23 and R 24 are independently hydrogen, halogen, alkyl or alkoxy, and pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable excipient, diluent or carrier suitable for delayed release oral administration.
2. A pharmaceutical composition comprising a compound having the formula
where R 1 and R 2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, or cycloalkyl having from 3 to about 6 carbon atoms, R 20 is hydrogen, phenyl or lower alkyl, W is carbon or nitrogen, R 23 and R 24 are independently hydrogen, halogen, alkyl or alkoxy, and pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable excipient, diluent or carrier suitable for delayed release oral administration.
3. A pharmaceutical composition comprising a compound having the formula
where R 1 and R 2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, or cycloalkyl having from 3 to about 6 carbon atoms, and pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable excipient, diluent or carrier suitable for delayed release oral administration.
4. A pharmaceutical composition comprising a compound having the formula
where R 1 and R 2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralkyl, or cycloalkyl having from 3 to about 6 carbon atoms, R 20 is hydrogen, phenyl or lower alkyl and pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable excipient, diluent or carrier suitable for delayed release oral administration.
5. The pharmaceutical composition of claim 4 where R 1 and R 2 are independently hydrogen and alkyl having from 1 to about 2 carbon atoms and R 20 is hydrogen or lower alkyl.
6. The pharmaceutical composition of claim 5 where R 20 is hydrogen or methyl.
7. A pharmaceutical composition comprising a compound having the formula
where R 1 and R 2 are independently hydrogen, alkyl having from 1 to about 7 carbon atoms, aryl, aralky, or cycloalkyl having from 3 to about 6 carbon atoms, and pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable excipient, diluent or carrier suitable for delayed release oral administration.